Treatment interruption strategies: How great are the risks?

Current Opinion in Infectious Diseases

Volumn 21, Issue 1, 2008, Pages 25-30

  Paton, Nicholas I ^a,b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV; Opportunistic infections; Treatment interruption; Treatment strategies

Indexed keywords

EFAVIRENZ; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; REVIEW; THERAPY DELAY; TREATMENT OUTCOME;

HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 38149139519     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3282f4069d     Document Type: Review

References (32)

1. + T-cell recovery.
2. Walmsley SL, Thorne A, Loutfy MR, et al. A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164). J Acquir Immune Defic Syndr 2007; 45:418-425. A 12-week interruption did not increase the proportion of patients responding to salvage therapy.
3. Pai NP, Lawrence J, Reingold AL, Tulsky JP. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database Syst Rev 2006; 3:CD006148. This is a useful systematic review of studies in the setting of virological failure.
4. + T-cell counts at 12 months.
5. Bloch MT, Smith DE, Quan D, et al. The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). J Acquir Immune Defic Syndr 2006; 42:192-202. Hydroxyurea was not of benefit when used with structured treatment interruptions in acute infection.
6. Vogel M, Lichterfeld M, Kaufmann DE, et al. Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion. Eur J Med Res 2006; 11:273-278.
7. Jacobson JM, Pat Bucy R, Spritzler J, et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis 2006; 194:623-632. This study provides proof of the auto-vaccination hypothesis, albeit in the setting of chronic infection.
8. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. This massive study is one of the most important and influential trials ever conducted in HIV medicine. It has changed clinical practice and continues to provide a wealth of data that will shape our understanding of the pathogenesis of HIV disease and the benefits of antiretroviral therapy.
9. Skiest DJ, Su Z, Havlir DV, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 2007; 195:1426-1436.
10. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989. This SMART-like study performed in Africa showed even more dramatic negative clinical consequences of treatment interruption.
11. Deuffic-Burban S, Losina E, Wang B, et al. Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan. Cote d'Ivoire: impact of alternative methods of CD4 count modelling. Eur J Epidemiol 2007; 22:737-744.
12. + threshold than used in SMART or Trivacan may minimize clinical risks.
13. Hakim J, on behalf of the DART Team. A structured treatment interruption (STI) strategy of 12 week cycles on and off ART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomisation within the DART trial [abstract]. In: Proceedings of the XVI International AIDS Conference; 13-18 August 2006; Toronto, Canada. International AIDS Society: Geneva, Switzerland; 2006. http://www.aids2006.org/PAG/ Abstracts.aspx?AID=51163 [accessed 14 November].
14. + decline, although minor HIV-related events were more common.
15. + decline and emergence of resistance mutations.
16. Cohen CJ, Colson AE, Sheble-Hall AG, et al. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-dayson, two-days-off (FOTO) study. HIV Clin Trials 2007; 8:19-23. This is an interesting pilot study of an interruption strategy for people desiring drug-free weekends, which deserves evaluation in a large-scale randomized trial.
17. Rosenberg ES, Davidian M, Banks HT. Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection. Drug Alcohol Depend 2007; 88 (Suppl 2):S41-S51. Outlines a more systematic approach to designing future interruption interventions.
18. Breban R, Blower S. Role of parametric resonance in virological failure during HIV treatment interruption therapy. Lancet 2006; 367:1285-1289.
19. Cohn D, for the SMART Study Group. Severity and types of clinical events by proximal CD4 cell counts in the SMART study [abstract THPE0047]. In: Proceedings of the XVI International AIDS Conference; 13-18 August 2006; Toronto, Canada. International AIDS Society: Geneva, Switzerland; 2006. http://www.iasociety.org/Default.aspx?pageId=11&abstractId=2194513 [accessed 14 November 2007].
20. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957-1963. This study shows that non-AIDS-defining malignancies dominate in the HAART era.
21. Prineas R, Roediger M, Carr A, et al. Effect of alternate treatment protocols on the incidence of electrocardiographic abnormalities among HIV infected adults in the SMART trial [abstract WEPEB077]. In: Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia. International AIDS Society: Geneva, Switzerland; 2007. http://www.iasociety.org/Default.aspx?pageId=11& abstractId=200703664 [accessed 14 November 2007]
22. Gordin F, Roediger M, Clezy K, et al. An increased risk of bacterial pneumonia in patients interrupting antiretroviral treatment: results from the SMART study [abstract MOPEB100]. In: Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia. International AIDS Society: Geneva, Switzerland; 2007. http://www.iasociety. org/Default.aspx?pageId=11&abstractId=200701627 [accessed 14 November 2007].
23. Tedaldi E, Puoti M, Neuhaus J, et al. Opportunistic disease and mortality in patients co-infected with hepatitis C virus (HCV) and/or hepatitis B virus (HBV) in the SMART (Strategic Management of Antiretroviral Therapy) study [abstract TUAB203]. In: Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia. International AIDS Society: Geneva, Switzerland; 2007. http://www.iasociety.org/ Default. aspx?pageId=11&abstractId=200703450 [accessed 14 November 2007].
24. Dore G, Soriano V, Neuhaus J, et al. Higher rate of antitretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic therapy arm of the SMART study [abstract TUAB204]. In: Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia. International AIDS Society: Geneva, Switzerland; 2007. http://www.iasociety.org/Default.aspx?pageId=11&abstractId= 200704389 [accessed 14 November 2007].
25. Burman W, Grund B, Neuhaus J, et al. The effect of episodic ART on HIV transmission risk: a substudy of the SMART study [abstract 979]. In: Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California. Alaexandria, Virginia: Conference on Retroviruses and Opportunistic Infections; 2007. http://www. retroconference.org/2007/Abstracts/28742.htm [accessed 14 November 2007].
26. Libois A, Lopez A, Garcia F, et al. Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. AIDS Res Hum Retroviruses 2006; 22:657-666.
27. Boom J, Kosters E, Duncombe C, et al. Ferritin levels during structured treatment interruption of highly active antiretroviral therapy. HIV Med 2007; 8:388-395.
28. Arjona MM, Perez-Cano R, Garcia-Juarez R, et al. Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: effects on leptin and TNF-alpha. AIDS Res Hum Retroviruses 2006; 22:307-314.
29. Taylor S, Boffito M, Khoo S, et al. Stopping antiretroviral therapy. AIDS 2007; 21:1673-1682. This is a useful review of stopping strategies to avoid NNRTI resistance.
30. Kikaire B, Khoo S, Walker AS, et al. Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS 2007; 21:733-737. This study shows prolonged clearance of nevirapine in African patients interrupting therapy, suggesting the need for a longer period of NRTI cover.
31. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401-407. This important study demonstrates the effect of genetic variability on efavirenz clearance.
32. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society: USA panel. JAMA 2006; 296:827-843.